Matthew Foy is a Partner of SROne, a biotech venture capital firm owned by GlaxoSmithKline. Matthew is part of the team responsible for investing SROne’s recently formed UK fund, of which PsiOxus is the second investment (Mission Therapeutics being the first). Prior to joining SROne, Matthew was a Consultant for Longbow Capital Partners and previously spent eight years in the New York and London offices of Greenhill and Co, a mergers and acquisitions investment bank, where he was a Vice President. Matthew holds a BSc and an MA in molecular biology from St Peters College, Oxford University; a Certificate in Corporate Finance from The London Business School and various qualifications from the SEC and FSA. Matthew Foy is a Partner of SROne, a biotech venture capital firm owned by GlaxoSmithKline. Matthew is part of the team responsible for investing SROne’s recently formed UK fund, of which PsiOxus is the second investment (Mission Therapeutics being the first). Prior to joining SROne, Matthew was a Consultant for Longbow Capital Partners and previously spent eight years in the New York and London offices of Greenhill and Co, a mergers and acquisitions investment bank, where he was a Vice President. Matthew holds a BSc and an MA in molecular biology from St Peters College, Oxford University; a Certificate in Corporate Finance from The London Business School and various qualifications from the SEC and FSA.

fermentation